Materials
5-(aminopentynyl)-2'-deoxycytidine triphosphate 1 was prepared according to the literature. 6-Maleimidohexanoic acid N-hydroxysuccinimide ester, DBCO-PEG4-NHS were purchased from Sigma Aldrich. Other chemicals were purchased from commercial suppliers and were used as received. Flash chromatography was performed using Merck silica gel G60 (230-400 mesh) and Merck precoated plates (silica gel 60 F254) were used for TLC. Reversed phase high pressure liquid chromatography (RP-HPLC) for the purification of compounds was performed using a Shimadzu system having LC8a pumps and a Dynamax UV-1 detector. A VP 250/16 NUCLEODUR C18 HTec, 5 μm (Macherey-Nagel) column and a gradient of acetonitrile in 50 mM TEAA buffer were used. All nucleotides purified by RP-HPLC were obtained as their triethylammonium salts after repeated freeze-drying. NMR spectra were recorded on Bruker Avance III 400 (1 H: 400 MHz, 13 C: 101 MHz, 31 P: 162 MHz) or Bruker Avance III 600 (1 H: 600 MHz, 13 C: 150 MHz, 31 P: 243 MHz) spectrometer. The solvent signals were used as references and the chemical shifts converted to the TMS scale and are given in ppm (δ). HR-ESI-MS spectra were recorded on a Bruker Daltronics microTOF II.
DNA polymerases were expressed and purified as described before. 2 T4 polynucleotide kinase PNK was purchased from New England BioLabs. Oligonucleotides were purchased from Biomers.net.
[γ-32P]ATP was purchased from Hartmann Analytics and natural dNTPs from Thermo Scientific. Streptavidin sepharose high performance was purchased from GE Healthcare (Matrix: highly crosslinked agarose, 6%; binding capacity/ml: >300 nmol biotin/ml medium; average particle size: 34 μm). Primary and secondary antibodies were purchased from Thermo Scientific.
Synthesis of 16-azidohexadecanoic acid
To a stirred solution of 16-bromohexadecanoic acid (1 g, 2.98 mmol, 1 eq.) in DMF was added NaN3 (0.39 g, 5.96 mmol, 2 eq.). Then the reaction mixture was warmed to 100 °C and refluxed for 16 h, then cooled to room temperature. The mixture was extracted with ethyl acetate (3x50 mL) and the combined organic phase was washed with water (3x50 mL) and brine (50 mL) and dried over MgSO4 and then it was concentrated to get 16-azidohexadecanoic acid. The product was isolated as a white solid (0.7 g, 79 %).
1 H NMR (400 MHz, CDCl3): 1 H NMR (400 MHz, CDCl3): δ 3.25 (t, J=7.0 Hz, 2H, H-16), 2.35 (t, J=7.5 Hz, 2H, H-2), 1.69-1.54 (m, 4H, H-3, H-15), 1.42-1.21 (m, 22H, H-4-14) .
13 C NMR (101 MHz, CDCl3): δ 179. 75, 51.66, 34.12, 29.76, 29.72, 29.68, 29.63, 29.57, 29.38, 29.30, 29.21, 28.99, 26.87, 24.84. 
Synthesis of 5-[5-(16-azidohexadecanamido)pent-1-yn-1-yl]-2'-deoxycytidinetriphosphate
To a solution of 16-azidohexadecanoic acid (0.05 g, 0.18 mmol, 2 eq.) in DMF (2 ml) was added Et3N (62 µl, 0.45 mmol, 5 eq.) followed by HATU (0.07 g, 0.18 mmol, 2 eq.). The mixture was stirred for 15 min at rt and then 5-(aminopentynyl)-2'-deoxycytidine triphosphate (0.05 g, 0.09 mmol, 1 eq.) was added and mixture was stirred for 16 h at rt. The solvent was removed and the product was purified from the crude reaction mixture by RP-HPLC on a C18 column (95% 50 mM triethylammonium acetate (TEAA) buffer to 100% MeCN). The product was isolated as a white solid (26 mg, 35 %). 
Synthesis of antibody-labeled nucleotide (dC pAb TP)
The antibody was first reacted with DBCO-PEG4-NHS following a standard procedure for antibody conjugation through the NH2 group. In brief, primary (mouse monoclonal IgG1-Apoliprotein A1 monoclonal antibody, 100 µg in PBS buffer) was incubated with DBCO-PEG4-NHS (5 eq.) in PBS buffer (pH 7.4) for 2 h at rt. After reaction, the free DBCO-PEG4-NHS was removed using the Amicon Ultra Centrifugal Filter (50 kDa). To determine the number of DBCO molecules on the antibody, the absorbance at 309 and 280 nm was measured. The molar concentrations of DBCO and antibody were determined using their respective molar extinction coefficient (12 000 M -1 cm -1 for DBCO at 309 nm and 204 000 M -1 cm -1 for antibody at 280 nm). The number of DBCO molecules per antibody was calculated by dividing the molar concentration of DBCO by the molar concentration of antibody. We obtained 3.1 DBCO molecules per pAb after reaction. The DBCO-functionalized antibody reacted with azide-modified nucleotide (dC C16N3 TP, 10 eq.). The reaction was conducted at 4 °C for 16 h. The solution was purified either by anion exchange FPLC (HiTrap Q HP, GE Life Science) with a gradient from Buffer A (20 mM TRIS, pH 9) to Buffer B (20 mM TRIS, 1 M NaCl, pH 9) or by the Amicon Ultra Centrifugal Filter Amicon Ultra Centrifugal Filter (10 kDa). The final concentration of the obtained conjugate was determined using their respective molar extinction coefficient (204 000 M -1 cm -1 at 280 nm).
Primer extension experiments
The reaction mixture (10 μL) contained DNA polymerase (KTq 100 nM, KOD 150 nM, 9°N 150 nM), template (Template BRAF , 0.2 μM), primer (Primer BRAF , 0.15 μM), modified dNTPs (1 μM) and unmodified dATP, dTTP, dGTP and dC pAb TP (for experiment in Figure 2 lane BRAF-I, each 1 μM) in 1x polymerase buffer (DNA sequences see table S1, buffer composition see table S2 ). Primer was labeled by use of [γ 32 P]ATP according to standard techniques. Reaction mixtures were incubated for time points at 55 °C and analysed by 9% PAGE electrophoresis.
6 Primer extension experiment on streptavidin-coated sepharose beads (dC pAb TP)
10 μL of a streptavidin-coated sepharose bead slurry (GE Life Science) were spun down (2400 x g) and the supernatant was discharged carefully. The beads were then washed three times with 100 μL 1 x binding buffer and 9.5 μL binding buffer and 0.5 μL 5'-biotinylated primer (Primer BIOTIN-BRAF , 100 μM) were added. Following 30 min of incubation with gentle mixing, 5.5 μL of 1 mM (D)-+-biotin in binding buffer were added to block the remaining streptavidin moieties. After further 10 min, the beads were spun down again and washed three times with 200 μL binding buffer and three times with 200 μL 1x polymerase buffer. For the primer extension reaction, 22.4 μL milliQ, 3 μL 10x polymerase buffer and 1 μL template (Template BRAF-MATCH ) were added to the beads and the mixture was mixed every minute for 10 min to prevent the beads from settling down in the tube. Subsequently, DNA polymerase and 1 μL of 5 μM dC pAb TP were added. The reaction mixture was incubated at 55°C for 5 min, then the beads were spun down and transferred to an empty spin column cartridge. After removing the reaction mixture by short spin centrifugation in a table top centrifuge, the beads were washed three times with 200 μL 1x polymerase buffer and five times with 200 μL PBS buffer (pH 7.4) and 29 μL PBS buffer and 1 μL of 0.1 mg/ml secondary antibody (goat anti-mouse IgG H+L Superclonal, HRP) was added to the reaction mixture and incubated for 4h at rt and then beads were washed 5 times with PBS buffer (pH 7.4) for 5 minutes.
Visualization with o-dianisidine:
The reaction mixture was washed 5 times with 200 μL detection buffer I. Subsequently, the supernatant was discharged and 20 μL of the developing solution was applied (1 mM o-dianisidine/H2O2 in detection buffer I). The reaction was quenched by the addition of 5 μL of 10 N sulfuric acid. Absorptions were measured with a Nanodrop ND-1000 spectrometer at 450 nm and 520 nm. Pictures were taken with a digital camera. Visualization with Amplex red: The reaction mixture was washed 5 times with 200 μL detection buffer II. Subsequently, the supernatant was discharged and 20 μL of the developing solution was applied (250 μM Amplex red/H2O2 in detection buffer II). Absorption was measured with a Nanodrop ND-1000 spectrometer at 570 nm. Pictures were taken with a digital camera.
The antibody-modified DNA was incubated with the secondary antibody (goat anti-mouse IgG H+L Superclonal, HRP, final concentration is 3.3 µg/ml) for 2 hours at rt. We found that at higher concentration of the secondary antibody the background signal increased. The reaction condition and the purification process (to remove any unbound antibody-labeled nucleotide and the secondary antibody) were optimized in order to determine the detection limit and exclude the possibility of non-specific binding. Table S1 . Primers and templates used for PEX experiments.
Sequences of primers and templates
[a]
Sequences Primer
[a] In the template, segments that form a duplex with the primer are in bold. First incorporation site is underlined, expected incorporation sites are marked in italic. Table S2 . Buffers and solutions.
Buffers and solutions

TEAA buffer
50 mM triethylammonium acetate, pH 7
10x KTq reaction buffer 160 mM Tris, 500 mM (NH4)2SO4, 25 mM MgCl2, 1% Tween 20, pH 9.2 10x KOD reaction buffer 160 mM Tris, 500 mM (NH4)2SO4, 25 mM MgCl2, 1% Tween 20, pH 8 Figure 2 . SDS-PAGE of PEX single and multiple incorporation of the modified nucleotide (dC pAb TP). Autoradiography of a primer extension reaction employing the conjugate (dC pAb TP) with KOD DNA polymerase on templates containing the BRAF T1796A point mutation site with mismatch pairings and multiple incorporation sites (see sequence table); Samples were collected after 5 min and 30 min and resolved on a 7.5-12.5% SDS-PAGE gradient gel. L: Marker.
Primer extension experiments with mismatch and multiple incorporation templates -SDS-PAGE
Competition experiments
A typical competition experiment (10 μL) employing KOD DNA polymerase contained 1x polymerase reaction buffer, 32 P-labelled primer (Primer BRAF , 0.15 μM), template (Template BRAF , 0.2 μM), ratio dCTP: dC pAb TP mixture, and KOD DNA polymerase (150 nM). First primer and template were annealed. Afterwards the primer-template complex, nucleotides and DNA polymerase were incubated (55 °C; 5 min). The reactions were quenched by addition of PAGE gel loading buffer/stop solution and the product mixtures were analysed by 12% denaturing polyacrylamide gel and subjected to autoradiography. Quantification was done by using the Bio-Rad Quantity One software. The conversion in percent was plotted versus the concentration using the program ImageLab. 
